Hormone-refractory prostate cancer+2
Not recruitingStudy of Fuzuloparib, Abiraterone Acetate, and Prednisone for First-Line Treatment in Patients with Metastatic Castration-Resistant Prostate Cancer
Study of Fuzuloparib, Abiraterone Acetate, and Prednisone for First-Line Treatment in Patients with Metastatic Castration-Resistant Prostate Cancer
- Disease:Hormone-refractory prostate cancerProstate cancer metastatic+1
- Substances:Abiraterone AcetatePrednisone+1
Belgium- Participants:18–64 years · 65+ years
- Substances:Abiraterone Acetate








